Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 8/20 | 0.32 |
| ▸ | DRD1 | P21728 | 7/20 | 0.32 |
| ▸ | DRD5 | P21918 | 6/20 | 0.32 |
| ▸ | DRD4 | P21917 | 5/20 | 0.32 |
| ▸ | DRD3 | P35462 | 5/20 | 0.32 |
| ▸ | DRD2 | P14416 | 5/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9914897 | 0.79 | KEAP1 (0.42) | HPGDCYP3A4 | |
| SCHEMBL9913592 | 0.78 | HTR6 (0.49) | HPGDTSHRL3MBTL1LMNA | |
| SCHEMBL9914924 | 0.76 | PTGER3 (0.40) | — | |
| SCHEMBL2453125 | 0.67 | CDK4 (0.42) | HPGDTSHRL3MBTL1LMNA | |
| SCHEMBL20937418 | 0.65 | CYP1A2 (0.43) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9913593 | 0.64 | HDAC1 (0.52) | HPGDTSHRL3MBTL1LMNA | |
| SCHEMBL30094656 | 0.62 | ALOX5AP (0.43) | SMN1; SMN2FFAR1L3MBTL1LMNA | |
| SCHEMBL11869553 | 0.62 | ALOX5AP (0.43) | SMN1; SMN2FFAR1L3MBTL1LMNA | |
| SCHEMBL12578542 | 0.61 | ALOX5AP (0.40) | HPGDSMN1; SMN2FFAR1HRH1DRD2 | |
| SCHEMBL7003874 | 0.61 | KDM4E (0.40) | FFAR1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198274-B2 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100016312-A1 | Substituted indolyl and indazolyl derivatives and uses thereof | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016312-A1 | Substituted indolyl and indazolyl derivatives and uses thereof | MAOB, MAOA, TPH1 | HPGD 1042/4885SMN1; SMN2 1302/4885FFAR1 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.